Rosen Law Firm Urges ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm Urges ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026 inclusive (the “Class Period”). ARS Pharmaceuticals is a clinical stage biopharmaceutical company.

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.

The Allegations: Rosen Law Firm is Investigating the Allegations that ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Misled Investors Regarding its Business Operations.

According to the lawsuit, defendants provided investors with material information concerning ARS Pharmaceuticals' expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Defendants’ statements included, among other things, confidence that this coverage would begin on July 1, 2026, and be in place for the summer and back-to-school allergy seasons.